Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021

BACKGROUND: Up-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions. AIM: We estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign. METHODS: We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Stringhini, Silvia, Zaballa, María-Eugenia, Pullen, Nick, Perez-Saez, Javier, de Mestral, Carlos, Loizeau, Andrea Jutta, Lamour, Julien, Pennacchio, Francesco, Wisniak, Ania, Dumont, Roxane, Baysson, Hélène, Richard, Viviane, Lorthe, Elsa, Semaani, Claire, Balavoine, Jean-François, Pittet, Didier, Vuilleumier, Nicolas, Chappuis, François, Kherad, Omar, Azman, Andrew S., Posfay-Barbe, Klara, Kaiser, Laurent, Guessous, Idris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555371/
https://www.ncbi.nlm.nih.gov/pubmed/34713799
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.43.2100830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555371/
https://www.ncbi.nlm.nih.gov/pubmed/34713799
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.43.2100830

Ejemplares similares